A newly published review in Digestive Diseases and Sciences synthesizes what we know about celiac disease in 2026—and the picture it paints is both sobering and familiar to anyone navigating this condition. Researchers Dominic Amakye from the University of Tennessee Health Science Center and Kofi Clarke from Penn State’s Division of Gastroenterology surveyed the current landscape of epidemiology, disease mechanisms, and therapeutic strategies. Their conclusion reinforces what celiac families already live with daily: we still have only one treatment, adherence is brutal, and underdiagnosis remains a persistent problem.
For those of us raising children with celiac disease, this review serves as a reminder that the medical establishment is still catching up to a condition that affects roughly 1% of the global population.
The Underdiagnosis Problem Persists
The review confirms that celiac disease affects between 0.7% and 1.4% of people worldwide, yet a significant portion of cases go undetected. The culprit? Variable clinical presentations. Celiac disease doesn’t announce itself consistently. Some patients present with classic gastrointestinal symptoms—diarrhea, bloating, abdominal pain. Others show up with anemia, fatigue, osteoporosis, or neurological symptoms. Some have no obvious symptoms at all.
This variability means celiac disease can hide in plain sight. As I’ve written about before, fatigue and poor health outcomes plague the celiac community even after diagnosis, partly because many patients spend years symptomatic before anyone thinks to test them.
Many celiac families assume the hardest part is behind them once they have a name for what was wrong. What can be harder to anticipate is how many people never get that far — how many children and adults are walking around with undiagnosed celiac disease, their symptoms attributed to stress, irritable bowel syndrome, or simply being “sensitive.”
The Genetic Complexity
One valuable contribution of this review is its summary of the genetic architecture underlying celiac disease. The condition occurs predominantly in individuals carrying the HLA-DQ2, HLA-DQ8, or DQA1*05 haplotypes—but the authors note that “several other predisposing genes have been described.” This genetic complexity helps explain why celiac disease runs in families but doesn’t follow simple inheritance patterns.
Understanding the genetics matters for celiac parents. If my son has celiac disease, the rest of us carry elevated risk. First-degree relatives of celiac patients should be screened, yet many healthcare providers don’t mention this. The review’s emphasis on genetic susceptibility underscores why proactive screening in at-risk families could catch more cases before complications develop.
Diagnosis Still Requires Multiple Steps
The diagnostic pathway outlined in the review will be familiar to anyone who has been through it: positive serologic tests (IgA tissue transglutaminase antibodies, or IgG deaminated gliadin peptide for those who are IgA-deficient), characteristic histological findings on duodenal biopsy, and symptom resolution following initiation of a gluten-free diet.
That three-part requirement creates friction. Serology can be done with a blood draw, but biopsy requires endoscopy—an invasive procedure that’s particularly challenging to schedule for children. And the requirement that patients be eating gluten at the time of testing means anyone who has already gone gluten-free on suspicion must undergo a “gluten challenge,” deliberately eating gluten to provoke an immune response before testing can be accurate.
Emerging research suggests that serologic testing may eventually become reliable enough to reduce reliance on biopsy in certain cases. That day hasn’t arrived yet, but the possibility offers hope for less invasive diagnostic pathways in the future.
The Gluten-Free Diet: Still the Only Treatment
Perhaps the most frustrating takeaway from this comprehensive review is the confirmation that a strict gluten-free diet remains “the only effective treatment.” The authors note that symptom improvement typically occurs within weeks of starting the diet—which is true. What the clinical language doesn’t capture is what adherence actually costs.
Reading every label. Interrogating restaurant staff. Declining birthday cake at parties. Packing separate meals for school trips. Watching your child learn to say “I can’t eat that” before they fully understand why.
The review acknowledges that adherence is “often challenging” and “socially isolating.” These words barely scratch the surface. For celiac families, the gluten-free diet isn’t just a treatment protocol—it’s a complete reorganization of daily life. Every meal becomes a risk assessment. Every social gathering requires advance planning. Every lapse, intentional or accidental, can trigger days of symptoms and intestinal damage.
Complications of Poorly Controlled Disease
The review catalogs the complications associated with poorly controlled celiac disease: osteoporosis, malnutrition, vitamin deficiencies, and small bowel lymphoma. This list should motivate strict adherence, and it does—but it also adds to the psychological burden that celiac families carry.
Every accidental exposure becomes weighted with long-term fear. Was that enough gluten to cause damage? Is the diet strict enough? Are we doing this right? The stakes feel impossibly high, especially when you’re managing your child’s health.
This is why the lack of therapeutic alternatives matters so much. A backup treatment—something that could mitigate accidental exposures or reduce the burden of perfect adherence—would transform quality of life for millions of people. We’ve discussed the pipeline of potential treatments including luminal enzymes and oral immune tolerance approaches. None have reached clinical practice yet, but research continues.
What This Review Means for Families
Comprehensive reviews like this one serve an important function in medicine. They synthesize scattered research into a coherent picture, helping clinicians understand the current state of knowledge. For gastroenterologists who don’t specialize in celiac disease, this paper provides a useful update.
But for celiac families, the review reads as confirmation of what we already know too well. Diagnosis is difficult. Treatment is burdensome. The medical system is slowly improving but hasn’t yet delivered the breakthroughs we need.
What I take from this paper is the recognition that celiac disease demands more research investment, more clinician education, and more urgency. A condition affecting 1% of the population—with serious complications when untreated—deserves better than a treatment approach that requires patients to fundamentally restructure their lives and hope for perfect execution.
Looking Forward
The publication of comprehensive reviews signals that celiac disease is receiving serious academic attention. Amakye and Clarke have produced a resource that will help educate the next generation of physicians. Better-informed doctors mean faster diagnoses and fewer patients falling through the cracks.
For those of us in the celiac community, the path forward involves continued advocacy. We need to push for screening in at-risk populations. We need to support research into alternative treatments. We need to educate schools, restaurants, and food manufacturers about cross-contact risks. And we need to keep sharing our experiences so that the isolation the review describes becomes a little less complete.
My son will live with celiac disease for the rest of his life. I want the medical landscape he navigates as an adult to look very different from the one we have today. Reviews like this one—thorough, evidence-based, widely read—are part of building that better future.
Related Coverage
- Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
- Celiac Disease Tied to Fatigue, Poor Health, and Care Gaps - Medscape
References
Amakye D, Clarke K. Celiac Disease: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Strategies. Digestive Diseases and Sciences. 2026 Apr 13. doi: 10.1007/s10620-026-09860-3. PubMed